Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study)

The American Journal of Cardiology
V L SerebruanyCharles H Hennekens

Abstract

We investigated whether, in primary prevention patients with metabolic syndrome, statins affect the platelet protease-activated receptor-1 (PAR-1) thrombin receptor by performing serial measurements of its activity and the antigen expression level by flow cytometry before and during treatment. Recent data from randomized trials of statins are compatible with the possibility of clinically relevant pleiotropic effects. The use of statins is associated with a reduced thrombosis burden and diminished platelet activity, as shown in animal models and in vitro studies. Seventy patients with the metabolic syndrome who were not taking antiplatelet agents were assigned consecutively at starting doses at the discretion of the responsible clinician to 1 of 6 statins (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, or simvastatin) or to a no-statin group for 6 weeks. Platelet expression of intact (SPAN12 antibody) and cleaved (WEDE15) PAR-1 thrombin receptors were assessed by flow cytometry at baseline and at weeks 4 and 6 of treatment. At baseline, no difference was found in receptor expression. However, after 4 weeks of treatment, all statins had significantly inhibited (46% to 55%) the activated epitope of PAR-1 express...Continue Reading

References

Mar 20, 1993·Annals of the New York Academy of Sciences·K A Ault
Jul 23, 1997·JAMA : the Journal of the American Medical Association·P R HebertC H Hennekens
Mar 17, 1999·The Journal of Clinical Investigation·M L KahnS R Coughlin
Jan 6, 2001·The Annals of Pharmacotherapy·C G Sotiriou, J W Cheng
Jun 22, 2002·JAMA : the Journal of the American Medical Association·Patrick W J C SerruysUNKNOWN Lescol Intervention Prevention Study (LIPS) Investigators
Jan 11, 2003·The Journal of Biological Chemistry·Abdelkarim SabriSusan F Steinberg
Jan 24, 2004·Journal of Thrombosis and Thrombolysis·Raimondo De Cristofaro, Erica De Candia
Oct 13, 2004·Archives of Internal Medicine·Victor L SerebruanyCharles H Hennekens
Oct 27, 2004·Apoptosis : an International Journal on Programmed Cell Death·A N Flynn, A G Buret
Jan 7, 2005·Journal of Thrombosis and Haemostasis : JTH·S K MandalU R Pendurthi
Nov 9, 2005·Current Opinion in Lipidology·James K Liao

❮ Previous
Next ❯

Citations

Mar 28, 2008·Current Atherosclerosis Reports·Sarah P Towne, Eddie Thara
Jun 12, 2013·Current Infectious Disease Reports·Ammar HabibM Rizwan Sohail
Mar 8, 2008·Current Treatment Options in Cardiovascular Medicine·Wai Ping Alicia ChanJohn David Horowitz
May 14, 2009·Vascular Health and Risk Management·Paolo RubbaMarco Gentile
Aug 4, 2012·Hämostaseologie·T Wurster, A E May
Sep 3, 2013·Antioxidants & Redox Signaling·Francesco Violi, Pasquale Pignatelli
May 14, 2014·The American Journal of Cardiology·Ten-Fang YangLung-Wen Tsai
Nov 23, 2013·Trends in Cardiovascular Medicine·Francesco VioliPasquale Pignatelli
Jan 15, 2013·Translational Research : the Journal of Laboratory and Clinical Medicine·Roza Badr EslamSimon Panzer
Oct 29, 2011·Mayo Clinic Proceedings·Nandan S AnavekarLarry M Baddour
Apr 25, 2008·Heart Failure Clinics·Nitin MathurDouglas L Mann
Dec 15, 2007·Metabolism: Clinical and Experimental·Sofiya AlhassanChristopher D Gardner
May 20, 2008·Cardiovascular Therapeutics·Genovefa D KolovouDennis V Cokkinos
Aug 29, 2007·Pharmacotherapy·Kyle A Weant, Aaron M Cook
Feb 3, 2009·American Heart Journal·Rahman Shah
Mar 8, 2017·Current Opinion in Cardiology·Vanessa BianconiMatteo Pirro
May 8, 2008·Journal of Cardiovascular Pharmacology and Therapeutics·Michael S KostapanosMoses S Elisaf
Jan 7, 2009·Therapeutic Advances in Cardiovascular Disease·Manuel Rodríguez-YáñezJosé Castillo
Dec 22, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Robert D McBaneWaldemar Wysokinski
Jan 16, 2013·Circulation·Francesco VioliPasquale Pignatelli
Aug 12, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·Chike ObiRobert D McBane
Sep 22, 2012·Arteriosclerosis, Thrombosis, and Vascular Biology·Ran NiPeter L Gross
May 17, 2012·Stroke; a Journal of Cerebral Circulation·James S McKinney, William J Kostis
Jan 24, 2007·Journal of Neurochemistry·Leslie N Johnson-AnunaW Gibson Wood
Nov 23, 2011·Pharmacological Reviews·Patrizia GazzerroMaurizio Bifulco
Nov 10, 2010·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Geneviève RicardJean-Martin Boulanger
Jan 1, 2012·Hämostaseologie·T Wurster, A E May
Jan 25, 2021·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Gladys P VelardeDale F Kraemer
Feb 11, 2021·BioMed Research International·Antonio NennaMassimo Chello

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.